CD38 Specific Chimeric Antigen Receptor KHYG-1 Natural Killer Cells: A Potential "Off the Shelf" Therapy for Multiple Myeloma

被引：0

作者：

Stikvoort, Arwen ^{[1
]}

Sarkar, Subhashis ^{[2
]}

Poels, Renee ^{[1
]}

van de Donk, Niels W. C. J. ^{[1
]}

Zweegman, Sonja ^{[1
]}

O'Dwyer, Michael E. ^{[2
]}

Mutis, Tuna ^{[1
]}

机构：

[1] Vrije Univ Amsterdam, Med Ctr, Canc Ctr Amsterdam, Dept Hematol, Amsterdam, Netherlands

[2] Natl Univ Ireland Galway, Sch Med, Biomed Sci, Galway, Ireland

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-116403

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3261

引用

页数：3

共 50 条

[31] Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma
Feng, Yaru
Liu, Xiuying
Li, Xiaorui
Zhou, Yating
Song, Zhiru
Zhang, Jing
Shi, Bingjie
Wang, Jianxun
ONCOIMMUNOLOGY, 2021, 10 (01):
[32] Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells
An, Na
Hou, Yun Nan
Zhang, Qiao Xia
Li, Ting
Zhang, Qiong Li
Fang, Cheng
Chen, Huan
Lee, Hon Cheung
Zhao, Yong Juan
Du, Xin
MOLECULAR PHARMACEUTICS, 2018, 15 (10) : 4577 - 4588
[33] ALLOGENEIC TCRA/CD38 DOUBLE KNOCKOUT T-CELLS BEARING AN ANTI-CD38 CHIMERIC ANTIGEN RECEPTOR: AN IMPROVED IMMUNOTHERAPY FOR THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND MULTIPLE MYELOMA
Dusseaux, M.
Le Clerre, D.
Gouble, A.
Smith, J.
HAEMATOLOGICA, 2016, 101 : 122 - 123
[34] CD38 KO/CD38-CAR Human Primary Natural Killer Cells Enhance Cytotoxicity Against CD38-Expressing Primary Lymphoma, Leukemia, and Myeloma
Troy, Ella C.
Sezgin, Yasemin
Pereira, Marcelo De Souza
Caporale, Joseph
Behbehani, Gregory K.
Lyberger, Justin
Lee, Dean Anthony
Kararoudi, Meisam Naeimi
BLOOD, 2023, 142
[35] The transfection of natural killer T cells with a tumor-antigen specific chimeric antigen receptor (CAR) for melanoma immunotherapy
Simon, B.
Wiesinger, M.
Maerz, J.
Wistuba-Hamprecht, K.
Weide, B.
Schuler-Thurner, B.
Schuler, G.
Doerrie, J.
Uslu, U.
EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E56 - E57
[36] Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies
Kloess, Stephan
Oberschmidt, Olaf
Dahlke, Julia
Vu, Xuan-Khang
Neudoerfl, Christine
Kloos, Arnold
Gardlowski, Tanja
Matthies, Nadine
Heuser, Michael
Meyer, Johann
Sauer, Martin
Falk, Christine
Koehl, Ulrike
Schambach, Axel
Morgan, Michael A.
HUMAN GENE THERAPY, 2019, 30 (04) : 381 - 401
[37] Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide
Karvouni, Maria
Vidal-Manrique, Marcos
Susek, Katharina H.
Hussain, Alamdar
Gilljam, Mari
Zhang, Yanliang
Gray, J. Dixon
Lund, Johan
Kaufmann, Gunnar
Ljunggren, Hans-Gustaf
Ji, Henry
Lundqvist, Andreas
Wagner, Arnika K.
Guo, Wenzhong
Alici, Evren
CYTOTHERAPY, 2023, 25 (07) : 763 - 772
[38] Robo1-specific chimeric antigen receptor natural killer cell therapy for pancreatic ductal adenocarcinoma with liver metastasis
Li, Chaojie
Yang, Nannan
Li, Huashun
Wang, Zhongmin
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2020, 16 (02) : 393 - 396
[39] Identification and characterisation of transient receptor potential melastatin 2 and CD38 channels on natural killer cells using the novel application of flow cytometry
Cassandra Balinas
Helene Cabanas
Donald Staines
Sonya Marshall-Gradisnik
BMC Immunology, 20
[40] Identification and characterisation of transient receptor potential melastatin 2 and CD38 channels on natural killer cells using the novel application of flow cytometry
Balinas, Cassandra
Cabanas, Helene
Staines, Donald
Marshall-Gradisnik, Sonya
BMC IMMUNOLOGY, 2019, 20 (1)

← 1 2 3 4 5 →